AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca is conducting a Phase 1/2 open-label, multi-center study titled A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies. The study aims to evaluate the safety and efficacy of acalabrutinib in treating these conditions, which are significant due to the limited treatment options available for relapsed or refractory cases.
Intervention/Treatment: The study tests acalabrutinib, an experimental drug administered orally. It is designed to treat relapsed or refractory mantle cell lymphoma, chronic lymphocytic leukemia, and other B-cell malignancies by targeting specific pathways involved in cancer cell growth.
Study Design: This interventional study is non-randomized with a single-group assignment. It is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, aiming to assess the drug’s impact on the targeted conditions.
Study Timeline: The study began on April 29, 2020, with primary completion and estimated completion dates not specified. The latest update was submitted on July 8, 2025, indicating ongoing data collection and analysis.
Market Implications: The ongoing study of acalabrutinib could significantly impact AstraZeneca’s stock performance, as positive results may boost investor confidence and market share in the oncology sector. The study’s progress is crucial given the competitive landscape in cancer treatment, where advancements can lead to substantial financial gains.
The study is ongoing, with further details available on the ClinicalTrials portal.